GlaxoSmithKline (LON:GSK) has been assigned a GBX 1,320 ($18.24) target price by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Monday. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 2.25% from the company’s previous close.

GSK has been the subject of several other research reports. Goldman Sachs Group reissued a “buy” rating and set a GBX 1,900 ($26.25) price objective on shares of GlaxoSmithKline in a research report on Tuesday, October 17th. S&P Global set a GBX 1,500 ($20.72) price objective on GlaxoSmithKline and gave the company a “neutral” rating in a research report on Thursday, October 26th. HSBC reissued a “buy” rating and set a GBX 1,925 ($26.60) price objective on shares of GlaxoSmithKline in a research report on Wednesday, November 22nd. Morgan Stanley set a GBX 1,450 ($20.03) price objective on GlaxoSmithKline and gave the company a “sell” rating in a research report on Monday, November 6th. Finally, Kepler Capital Markets lowered their price objective on GlaxoSmithKline from GBX 1,520 ($21.00) to GBX 1,340 ($18.51) and set a “reduce” rating for the company in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 1,540.45 ($21.28).

GlaxoSmithKline (LON GSK) opened at GBX 1,291 ($17.84) on Monday. The company has a market capitalization of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($17.07) and a 52-week high of GBX 1,724.50 ($23.83).

In other GlaxoSmithKline news, insider Sir Roy Anderson bought 562 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was acquired at an average price of GBX 1,278 ($17.66) per share, with a total value of £7,182.36 ($9,923.13). Also, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.10), for a total value of £262,000 ($361,978.45). In the last three months, insiders acquired 590 shares of company stock valued at $754,966.

TRADEMARK VIOLATION WARNING: This news story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://theolympiareport.com/2018/02/14/jpmorgan-chase-co-reiterates-gbx-1320-price-target-for-glaxosmithkline-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.